Comparative Pharmacology
Head-to-head clinical analysis: CHLORAMPHENICOL SODIUM SUCCINATE versus XIMINO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORAMPHENICOL SODIUM SUCCINATE versus XIMINO.
CHLORAMPHENICOL SODIUM SUCCINATE vs XIMINO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversibly binds to the 50S ribosomal subunit, inhibiting peptidyl transferase activity and blocking protein synthesis in bacteria.
XIMINO is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
Intravenous, 50 mg/kg/day divided every 6 hours; maximum 4 g/day.
400 mg orally twice daily with food for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-3.5 hours in adults with normal renal and hepatic function. In neonates (first 2 weeks of life), half-life is prolonged to 10-24 hours due to immature hepatic conjugation. In patients with severe hepatic impairment, half-life may exceed 12 hours, necessitating dose adjustment.
Terminal elimination half-life: 8 hours (range 6-10 hours) in healthy adults; prolonged to 15-20 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 80-90% of the dose is excreted renally as unchanged drug and as the inactive chloramphenicol base (formed by hydrolysis in the liver and kidneys). Biliary excretion accounts for about 5-10%, with some enterohepatic circulation. Fecal excretion is negligible (<2%).
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites and unchanged drug; 10% metabolized via hepatic CYP3A4.
Category D/X
Category C
Antibiotic
Antibiotic